meloxicam 0.25 mg/kg; meloxicam 0.125 mg/kg; naproxen 10 mg/kg
Проводит Boehringer Ingelheim
Страница компанииA One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00279747/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 2–16 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 226 чел. во всех странах исследования.
- Центров в реестре: 4 в одном городе. Список — ниже на странице.
- Плановая дата окончания (01.2003) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 15 · невключение: 19
Критерии включения
- Male or female outpatients and inpatients aged 2 to 16 years
- Diagnosis of idiopathic arthritis of childhood by ILAR criteria:
- Age of onset less than 16 years
- Arthritis in one or more joints defined as swelling, or - if no swelling is present - limitation in range of joint movement with joint pain or tenderness, which is not due to primary mechanical disorders
- Duration of the disease > 6 weeks
- Type of onset of disease during the first 6 months classified as polyarthritis (5 joints or more; rheumatoid factor positive or negative), oligoarthritis (4 joints or fewer) or systemic arthritis
- Oligoarthritic, extended oligoarthritic or polyarthritic current course of disease
- Active arthritis as defined above of at least 2 joints
- At least 2 other abnormal variables of any of the 5 remaining core set parameters. The physician and the parent ratings must be at least 10 mm on a 100 mm VAS scale and the CHAQ score more than 0.
- Patients requiring therapy with NSAIDs, i.e., the patient fits into one of the following categories:
- New onset patient
- Patient in remission, but experiencing a flare and now requiring an NSAID
- Patient with insufficient therapeutic effect (ITE) or intolerability to another NSAID (other than Naproxen) and now must be changed
- Written informed permission given by the parent(s) or the subjects legally authorised representative in accordance with local legislation and ICH GCP
- Active assent given by the patient if the child is capable of understanding the given information (applies to children who have reached an intellectual age of 7 years or greater)
Критерии невключения
- Patients with systemic course of JRA (intermittent fever with or without rash or other organ involvement) or with current systemic involvement
- All rheumatic diseases not covered by the inclusion criteria
- Any finding indicating that the patient has a clinically significant other disease than JRA at the time of enrollment
- Patients with abnormal, clinically relevant laboratory values not related to their JRA
- Pregnancy or breast feeding
- Women of childbearing potential not using adequate contraception precaution: attention should be drawn to reports that NSAIDs were reported to decrease the effectiveness of intrauterine devices (R95-0164)
- History of bleeding disorders, gastrointestinal bleeding or cerebrovascular bleeding
- Active peptic ulcer within the last 6 months
- Treatment with more than one SAARD/DMARD (slow-acting antirheumatic drug/disease-modifying antirheumatic drug) during the last 3 months prior to study entry
- Change in treatment with SAARDs/DMARDs during the last 3 months prior to study entry or intended change during the trial duration
- Change in treatment with corticosteroids during the last month prior to study entry or intended change during the trial duration with exception of local therapy for uveitis
- One of the following therapies during the last 3 months prior to study entry or their intended use during the trial treatment period
- Systemic treatment (except for intra-articular injections) with corticosteroids at a dose higher than 10 mg/day or 0.2 mg/kg/day (prednisone equivalent), respectively (whichever is lower)
- Treatment with hydroxychloroquine at a dose higher than 10 mg/kg/day
- Treatment with cyclosporine at a dose higher than 5 mg/kg/day
- Treatment with methotrexate at a dose higher than 15 mg/m2/week
- Treatment with other cytotoxic agents, gold compounds, D-penicillamine, Enbrel (etanercept), biologic agents and experimentals
- Intra-articular injections of corticosteroids during the last month prior to study entry and intended injections during the first 4 weeks of the trial treatment period
- Concomitant administration of other NSAIDs (including topical forms for skin with exception of local therapy for uveitis) or analgesic agents except paracetamol or acetaminophen
Источник: ClinicalTrials.gov, NCT00279747 · запись обновлена в реестре 1 ноября 2013.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 22
- Response rates according to ACR Ped 30 — after 12 weeks of treatment
Цель исследования
A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.
Где проходит
4 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00279747 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.